• Je něco špatně v tomto záznamu ?

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial

A. Biondi, V. Gandemer, P. De Lorenzo, G. Cario, M. Campbell, A. Castor, R. Pieters, A. Baruchel, A. Vora, V. Leoni, J. Stary, G. Escherich, CK. Li, G. Cazzaniga, H. Cavé, J. Bradtke, V. Conter, V. Saha, M. Schrappe, M. Grazia Valsecchi,

. 2018 ; 5 (12) : e641-e652.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012082

BACKGROUND: The EsPhALL2004 randomised trial showed a 10% advantage in disease-free survival for short, discontinuous use of imatinib after induction compared with no use of imatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia receiving Berlin-Frankfurt-Münster chemotherapy and haemopoietic stem-cell transplantation (HSCT). Other contemporary studies showed an advantage from continuous protracted exposure to imatinib, challenging the indications to transplant. The EsPhALL2010 study was designed to assess whether imatinib given from day 15 of induction and continuously throughout chemotherapy led to a different outcome to that obtained in EsPhALL2004, despite decreasing the number of patients having HSCT. METHODS: This prospective, intergroup, open-label, single-arm clinical trial (EsPhALL2010) was done at 11 study groups across Europe, Chile, and Hong Kong. Patients aged 1-17 years with the translocation t(9;22)(q34;q11) who were recruited into national front-line trials for acute lymphoblastic leukaemia were eligible for this trial. Patients with abnormal renal or hepatic function or an active systemic infection were ineligible. Patients received imatinib 300 mg/m2 continuously from day 15 of induction during chemotherapy. Eligibility to HSCT depended on early morphological response and minimal residual disease. Imatinib was recommended throughout the first year after transplant. The co-primary endpoints were event-free survival and overall survival. All analyses were done in the intention-to-treat population. The trial is registered with the European Clinical Trials Database (EudraCT 2004-001647-30) and with ClinicalTrials.gov (NCT00287105) and is completed. FINDINGS: 158 patients were screened for eligibility, of whom 155 were enrolled between Jan 1, 2010, and Dec 31, 2014. 151 (97%) patients achieved first complete remission after induction and four after the consolidation phase, with 102 (66%) patients categorised as good risk and 53 (34%) as poor risk according to EsPhALL risk stratification criteria. 59 (38%) patients had HSCT during their first complete remission. 40 (26%) patients relapsed and 41 (26%) patients died during the study (25 [61%] during complete continuous remission, and 16 [39%] after relapse). The 5-year event-free survival was 57·0% (95% CI 48·5-64·6) and 5-year overall survival was 71·8% (63·5-78·5). 154 serious adverse events were reported in 80 (52%) of 155 patients. The most common toxicity was infection (61 [39%] patients, mostly bacterial); gastrointestinal disorders occurred in ten (6%) patients and osteonecrosis in eight (5%). Serious adverse events occurred mainly during high-risk blocks and delayed intensifications, including 14 fatal events (one in the consolidation phase, six in high-risk blocks, six in first delayed intensification, and one in second delayed intensification). INTERPRETATION: Although HSCT was done in a smaller proportion of patients in EsPhALL2010 than in EsPhALL2004, event-free and overall survival were similar between the two studies. Our data suggest that imatinib given early and continuously with intensive chemotherapy might increase toxicity. FUNDING: Projet Hospitalier de Recherche Clinique-Cancer and Novartis France; Bloodwise and Cancer Research UK; Ministry of Health, Czech Republic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012082
003      
CZ-PrNML
005      
20190415142119.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2352-3026(18)30173-X $2 doi
035    __
$a (PubMed)30501871
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Biondi, Andrea $u Pediatric Department, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy; Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy. Electronic address: abiondi.unimib@gmail.com.
245    10
$a Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial / $c A. Biondi, V. Gandemer, P. De Lorenzo, G. Cario, M. Campbell, A. Castor, R. Pieters, A. Baruchel, A. Vora, V. Leoni, J. Stary, G. Escherich, CK. Li, G. Cazzaniga, H. Cavé, J. Bradtke, V. Conter, V. Saha, M. Schrappe, M. Grazia Valsecchi,
520    9_
$a BACKGROUND: The EsPhALL2004 randomised trial showed a 10% advantage in disease-free survival for short, discontinuous use of imatinib after induction compared with no use of imatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia receiving Berlin-Frankfurt-Münster chemotherapy and haemopoietic stem-cell transplantation (HSCT). Other contemporary studies showed an advantage from continuous protracted exposure to imatinib, challenging the indications to transplant. The EsPhALL2010 study was designed to assess whether imatinib given from day 15 of induction and continuously throughout chemotherapy led to a different outcome to that obtained in EsPhALL2004, despite decreasing the number of patients having HSCT. METHODS: This prospective, intergroup, open-label, single-arm clinical trial (EsPhALL2010) was done at 11 study groups across Europe, Chile, and Hong Kong. Patients aged 1-17 years with the translocation t(9;22)(q34;q11) who were recruited into national front-line trials for acute lymphoblastic leukaemia were eligible for this trial. Patients with abnormal renal or hepatic function or an active systemic infection were ineligible. Patients received imatinib 300 mg/m2 continuously from day 15 of induction during chemotherapy. Eligibility to HSCT depended on early morphological response and minimal residual disease. Imatinib was recommended throughout the first year after transplant. The co-primary endpoints were event-free survival and overall survival. All analyses were done in the intention-to-treat population. The trial is registered with the European Clinical Trials Database (EudraCT 2004-001647-30) and with ClinicalTrials.gov (NCT00287105) and is completed. FINDINGS: 158 patients were screened for eligibility, of whom 155 were enrolled between Jan 1, 2010, and Dec 31, 2014. 151 (97%) patients achieved first complete remission after induction and four after the consolidation phase, with 102 (66%) patients categorised as good risk and 53 (34%) as poor risk according to EsPhALL risk stratification criteria. 59 (38%) patients had HSCT during their first complete remission. 40 (26%) patients relapsed and 41 (26%) patients died during the study (25 [61%] during complete continuous remission, and 16 [39%] after relapse). The 5-year event-free survival was 57·0% (95% CI 48·5-64·6) and 5-year overall survival was 71·8% (63·5-78·5). 154 serious adverse events were reported in 80 (52%) of 155 patients. The most common toxicity was infection (61 [39%] patients, mostly bacterial); gastrointestinal disorders occurred in ten (6%) patients and osteonecrosis in eight (5%). Serious adverse events occurred mainly during high-risk blocks and delayed intensifications, including 14 fatal events (one in the consolidation phase, six in high-risk blocks, six in first delayed intensification, and one in second delayed intensification). INTERPRETATION: Although HSCT was done in a smaller proportion of patients in EsPhALL2010 than in EsPhALL2004, event-free and overall survival were similar between the two studies. Our data suggest that imatinib given early and continuously with intensive chemotherapy might increase toxicity. FUNDING: Projet Hospitalier de Recherche Clinique-Cancer and Novartis France; Bloodwise and Cancer Research UK; Ministry of Health, Czech Republic.
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x terapeutické užití $7 D000068877
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    12
$a filadelfský chromozom $7 D010677
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x genetika $7 D054198
650    _2
$a prospektivní studie $7 D011446
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gandemer, Virginie $u CHU Hôpital Sud, Rennes, France.
700    1_
$a De Lorenzo, Paola $u Pediatric Department, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy; EsPhALL Trial Data Center, School of Medicine and Surgery, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Cario, Gunnar $u University Medical Center, Christian-Albrechts-University Kiel, Kiel, Germany.
700    1_
$a Campbell, Myriam $u Chilean National Pediatric Oncology Group, Hospital Roberto del Rio, Santiago, Chile.
700    1_
$a Castor, Anders $u Department of Pediatric Oncology, Skane University Hospital, Lund, Sweden.
700    1_
$a Pieters, Rob $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
700    1_
$a Baruchel, André $u Robert Debré Hospital, University Paris Diderot, Paris, France.
700    1_
$a Vora, Ajay $u Great Ormond Street Hospital for Children, London, UK.
700    1_
$a Leoni, Veronica $u Pediatric Department, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Stary, Jan $u University Hospital Motol and Charles University, Department of Pediatric Hematology and Oncology, Prague, Czech Republic.
700    1_
$a Escherich, Gabriele $u University Medical Center Eppendorf, Clinic of Pediatric Hematology and Oncology, Hamburg, Germany.
700    1_
$a Li, Chi-Kong $u The Chinese University of Hong Kong, Hong Kong, China.
700    1_
$a Cazzaniga, Giovanni $u Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Cavé, Hélène $u Robert Debré Hospital, University Paris Diderot, Paris, France.
700    1_
$a Bradtke, Jutta $u Department of Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany.
700    1_
$a Conter, Valentino $u Pediatric Department, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Saha, Vaskar $u Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
700    1_
$a Schrappe, Martin $u University Medical Center, Christian-Albrechts-University Kiel, Kiel, Germany.
700    1_
$a Grazia Valsecchi, Maria $u EsPhALL Trial Data Center, School of Medicine and Surgery, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
773    0_
$w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 5, č. 12 (2018), s. e641-e652
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30501871 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190415142142 $b ABA008
999    __
$a ok $b bmc $g 1391392 $s 1050387
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 5 $c 12 $d e641-e652 $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace